Results 21 to 30 of about 87,351 (255)
Memantine as an Augmentation Therapy for Anxiety Disorders
Case Reports in Psychiatry, 2012 Objective. Glutamate, an excitatory neurotransmitter in the central nervous system (CNS), may play a role in the development of anxiety. Memantine partially blocks N-methyl-D-aspartate (NMDA) receptors' glutamate channels located in the CNS.
Thomas L. Schwartz +2 more
doaj +3 more sources
Alpha-1 Antitrypsin Deficiency: Home Therapy
Frontiers in Pharmacology, 2021 While available in only a few countries, home therapy is a possible strategy for the treatment of alpha-1 antitrypsin deficiency. We want to describe our experience in the management of human alpha-1 antitrypsin using home care intravenous augmentation ...
Anna Annunziata +5 more
doaj +1 more source
Case report: Self-administration of alpha-1 antitrypsin therapy: a report of two cases
Frontiers in Pharmacology, 2023 Intravenous augmentation therapy with human alpha-1 proteinase inhibitor for the management of respiratory disease is recommended for people with alpha-1 antitrypsin deficiency (AATD) who are nonsmokers or former smokers.
Ana M. Escribano Dueñas +3 more
doaj +1 more source
Augmenting Exposure Therapy: Mobile Augmented Reality for Specific Phobia [PDF]
Frontiers in Virtual Reality, 2020 New technologies, such as virtual reality (VR) and augmented reality (AR), can be used as an add-on to exposure therapy for common anxiety disorders. While the benefits of VR for exposure therapy have already been demonstrated extensively in research, AR applications are only just becoming widely available.
De Witte, Nele +5 more
openaire +1 more source
Pindolol augmentation of antidepressant therapy [PDF]
British Journal of Psychiatry, 1998 BackgroundAntidepressant therapy is not always effective and is slow to take effect. In theory, these shortfalls may be caused by induction of neuronal negative feedback via pre-synaptic 5-HTIA receptors. Pindolol, an antagonist at somatodentritic pre-synaptic 5-HTIA receptors has been investigated as a potential accelerator and augmenter of ...
R, McAskill, S, Mir, D, Taylor
openaire +3 more sources
COPD, 2021 Pulmonary events (PEs) associated with alpha-1 antitrypsin deficiency (AATD) can have a severe clinical course and increase healthcare resource use (HRU). However, AATD-associated HRU and healthcare costs have not been extensively described.
Ernesto Mayen Herrera +4 more
doaj +1 more source
Long-term experience in the treatment of α1-antitrypsin deficiency: 25 years of augmentation therapy [PDF]
European Respiratory Review, 2015 Although it is often under-recognised, α1-antitrypsin deficiency (AATD) represents one of the most common genetic respiratory disorders worldwide. Since the publication of studies in the late 1980s, which demonstrated that plasma-derived augmentation ...
Helmut Teschler
doaj +1 more source
Frontiers in Sports and Active Living, 2021 Lower-limb weight-bearing load distribution in stationary standing influences the timing of rapid first step initiation of importance for functional movement activities and agility performance in sports.
Masahiro Fujimoto +4 more
doaj +1 more source
Journal of Orthopaedic Surgery and Research, 2022 Background Recently facet joint block has been increasingly used to relief the residual pain after vertebral augmentation, but whether it can be a complementary or alternative to vertebral augmentation remain largely unknown. Thus, we conducted this meta-
Zhi Chen +4 more
doaj +1 more source
Exploring the causes of augmentation in restless legs syndrome
Frontiers in Neurology, 2023 Long-term drug treatment for Restless Legs Syndrome (RLS) patients can frequently result in augmentation, which is the deterioration of symptoms with an increased drug dose.
Pengyu Zeng +7 more
doaj +1 more source